New GLP-1 alternative, eloralintide, leads to 20% weight loss in trial

Trial participants who used eloralintide, a new weight loss medication that, instead of focusing on the hormone GLP-1, targets a different hormone called amylin, lost as much as 20% weight.

About The Author

Jeffrey L. Klump

I am 62 years old and widowed with 2 children. I live in Creve Coeur, MO. USA which is a suburb of Saint Louis. I am a Digital Marketer, Blogger, Writer, SEO Expert, and Work from Home Business Opportunity Specialist. I am the owner & administrator of the MEK Enterprises Blog. Please contact me if you have any questions. Thank you.

See author's posts